On Monday, Spyre Therapeutics Inc (NASDAQ: SYRE) opened higher 3.66% from the last session, before settling in for the closing price of $23.5. Price fluctuations for SYRE have ranged from $10.91 to $31.35 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 44.65%. Company’s average yearly earnings per share was noted 31.44% at the time writing. With a float of $68.52 million, this company’s outstanding shares have now reached $77.59 million.
Spyre Therapeutics Inc (SYRE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Spyre Therapeutics Inc is 11.69%, while institutional ownership is 77.07%. The most recent insider transaction that took place on Nov 03 ’25, was worth 1,049,778. In this transaction Chief Executive Officer of this company sold 45,000 shares at a rate of $23.33, taking the stock ownership to the 701,907 shares. Before that another transaction happened on Nov 03 ’25, when Company’s Director proposed sale 90,000 for $24.46, making the entire transaction worth $2,201,400.
Spyre Therapeutics Inc (SYRE) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.81 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.94) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.23% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Check out the current performance indicators for Spyre Therapeutics Inc (SYRE). In the past quarter, the stock posted a quick ratio of 10.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
The latest stats from [Spyre Therapeutics Inc, SYRE] show that its last 5-days average volume of 0.59 million was inferior to 0.68 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 66.03%.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 93.71%, which indicates a significant increase from 82.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.42 in the past 14 days, which was higher than the 1.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.78, while its 200-day Moving Average is $17.50. Now, the first resistance to watch is $25.24. This is followed by the second major resistance level at $26.13. The third major resistance level sits at $27.23. If the price goes on to break the first support level at $23.25, it is likely to go to the next support level at $22.15. The third support level lies at $21.26 if the price breaches the second support level.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are currently 77,592K shares outstanding in the company with a market cap of 1.89 billion. Presently, the company’s annual sales total 0 K according to its annual income of -208,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -11,180 K.
